spacer
home > pmps > summer 2018 > driving digitalisation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Driving Digitalisation

Pharmaceutical manufacturers are faced with the task of bringing new drugs to market as quickly as possible, without any compromise on quality or patient safety. A key driver of this demand is the time pressure faced in relation to the expiry of patents. Therefore, manufacturers need to move from R&D to production in the shortest possible time with minimum investment. Digitalisation and the adoption of emerging industrial digital technologies are set to play key parts in the delivery of such objectives.

Digitalisation is the technology focus behind Industry 4.0, and the central message about how it can enhance manufacturing and production capabilities is gaining steady traction. Advocates say its data-driven, highly connected world of seamless technology platforms will drive productivity improvements, promote agile production, aid competitiveness, and, ultimately, build business value and boost economic success.

The recent publication of the government-backed Made Smarter Review has set out a clear road map for the wide-scale adoption of emerging industrial digitalisation technologies and articulates how this can have a significant and positive economic impact. This includes a predicted £455 billion boost for the UK’s manufacturing base, an increase in manufacturing sector growth of up to 3% per annum, a net gain of 175,000 jobs, and a reduction of CO2 emissions by 4.5%.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Alwyn Jones has over 20 years’ experience in automation and engineering, working with market-leading companies, supplying systems and solutions into the highly regulated industry sectors. At Siemens, he is Head of Pharmaceutical and Life Sciences and manages the UK and Ireland pharmaceutical and life sciences sector strategy, helping manufacturers bring new and affordable drugs to market in the shortest possible time, without any compromise on quality.
spacer
Alwyn Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

The EC Definition of a Nanomaterial - Potential Measurement Methodologies

NanoSight

In October 2011 the European Commission published a definition of Nanomaterials. This move followed more than six years of scientific consideration of the potential toxicological and environmental challenges posed by engineered nanomaterials.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement